Inhibition of catechol-O-methyltransferase. Optimizing the dopaminergic therapy with entacapone in Parkinson's disease;Hemmung der catechol-O-methyltransferase. Optimierung der dopaminergen therapie beim idiopathischen Parkinsonsyndrom mit entacapone

Nervenarzt

Volumn 71, Issue 2, 2000, Pages 78-83

  Arnold, G ^a   Kupsch, A ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

COMT inhibition; Entacapone Tolcapone; Idiopathic Parkinson syndrome

Indexed keywords

CATECHOL METHYLTRANSFERASE; ENTACAPONE; TOLCAPONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENZYME INHIBITION; HEPATITIS; HUMAN; PARKINSON DISEASE; REVIEW;

ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CLINICAL TRIALS; DOPAMINE; HUMANS; NITROPHENOLS; PARKINSON DISEASE;

EID: 0034106475     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050011     Document Type: Review

References (28)

1. Ahtila S, Kaakkola S, Gordin A et al. (1995) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 18:46-57
2. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR (1998) Tolcapone and fulminat hepatitis. Lancet 352:958
3. Baas H (1998) Diskussion. Aktuel Neurol 25 [Suppl 4]:282
4. Brannan T, Prikkhojan A, Yahr MD (1997) Peripheral and central inhibitors of catechol-O-methyltransferase: effects on liver and brain COMT activity arid L-Dopa metabolism. J Neural Transm 104:77-87
5. DeSanti C, Giulianotti PC, Pietrabissa A, Mosca F, Pacifici GM (1998) Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur J Clin Pharmacol 54:215-219
6. Doudet DJ, Chan GL, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ (1997) Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 36:363-371
7. Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E (1997) Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov Disord 12:928-934
8. Jorga KM, Fotteler B, Heizmann P, Zurcher G (1998) Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Pharmacol 54:443-447
9. Jorga KM, Fotteler B, Sedek G, Nielsen T, Aitken J (1998) The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 245:223-230
10. Kaakkola S, Gordin A, Mannisto PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 25:813-824
11. Keränen T, Gordin A, Karlsson M et al. (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46:151-157
12. Larsen KR, Dajani EZ, Dajani NE, Dayton MT, Moore JG (1998) Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and sinemet on intestinal electrolyte and fluid transport in conscious dogs. Dig Dis Sci 43:1806-1813
13. Lautala P, Kivimaa M, Salomies H, Elovaara E, Taskinen J (1997) Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. Pharm Res 14:1444-1448
14. Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, Männistö PT (1998) No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthezised rats. Eur J Pharmacol 356:127-137
15. Männistö PT (1994) Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1:172-179
16. Männistö PT, Kaakkola S, Nissinen E, Linden IB, Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43:1465-1471
17. McNeely W, Davis R (1997) Entacapone. CNS Drugs 8:79-88
18. Mylylä VV and the Filomen Study Group (1998) Long-term safety of entacapone as adjunct ot levodopa in patients with Parkinson's disease. Mov Dis 13 [Suppl 2]:294
19. Nissinen E, Kaheinen P, Penttila KE, Kaivola J, Linden IB (1997) Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 340:287-294
20. Nissinen E, Linden IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346:262-266
21. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients. Ann Neurol 42:747-755
22. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, Nomecomt Study Group (1998) Entacapone enhances the response in parkinsonian patients with motor fluctuations. Neurology 51:1309-1314
23. Ruottinen HM, Rinne UK (1996) Entacapone prolongs levodopa respone in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiat 60:36-40
24. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T (1993) The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36:451-456
25. Törnwall M, Männistö PT (1991) Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol Toxicol 69:64-70
26. Trocóniz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A Karlsson MO (1998) Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther 64:106-116
27. Waters CH, Kurth M, Bailey P et al. (1997) Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49:665-671
28. Wikberg T, Vuorela A, Ottoila P, Taskinen J (1993) Identifications of major metabolites of the catechol-O-tranferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92